MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
Slapwoods is announcing its first-ever official collaboration with DJ Screw, the late Houston legend whose…
It could be so easy to believe that cannabis culture is something that has been…
Modern cultivation techniques and spiritual practices collide with Pink Boost Goddess on our next Legendary…
Animal rescuers and advocacy groups say dogs living on Skid Row are suffering from neglect,…
This article originally appeared in High Times’ 50th Anniversary print issue. It is an excerpt…
How Montana built a legal cannabis market from a thin medical marijuana law, federal raids,…